Email Alert | RSS    帮助

中国防痨杂志 ›› 2006, Vol. 28 ›› Issue (5): 274-277.

• 论著 • 上一篇    下一篇

固定剂量复合剂在省结核病防治规划中应用的研究

钟球1;黄桂清1;张明2;张日东2;李建伟1;   

  1. 1广东省结核病防治研究所 广州 510630;2佛山市慢性病防治院 佛山 528000;
  • 出版日期:2006-05-10 发布日期:2006-11-03

Study on using fixed-dose combinations in Provincial Tuberculosis Programe

Zhong Qiu1,Huang Guiqing,Zhang Ming,et al.   

  1. 1.Anti-tuberculosis Research Institute of Guangdong Province,Guangzhou 510630, China
  • Online:2006-05-10 Published:2006-11-03

摘要: 目的研究固定剂量复合剂在省结核病防治规划中应用的可行性。方法将初治涂阳肺结核病人按登记序号单双分入研究组和对照组。用对照研究方法对两组的完成治疗率、治疗效果、治疗依从性和不良反应等情况进行分析。结果研究组和对照组在性别、年龄、体重、完成治疗率、督导管理方式和治疗依从性等方面差异无显著性(P值均>0.05)。研究组的2、3个月未痰菌阴转率和治愈率分别为87.0%、93.5%和93.5%,对照组的2、3个月未痰菌阴转率和治愈率分别为89.4%、93.5%和87.0%,两组间的疗效差异无显著性(P值均>0.05)。除因链霉素引起的耳鸣(精确概率法P=0.024)外,两组其他不良反应症状出现的比例都无显著性差异(P值均>0.05)。结论在结核病防治规划中推广应用固定剂量复合剂是可行的。

关键词: 结核,肺/预防和控制, 化学疗法, 固定剂量复合剂

Abstract: Objective To study the feasibility of using fixed-dose combinations in Provincial Tuberculosis(TB) Programe. Method According to the registered serial number,the new smear-positive pulmonary TB cases were distributed into study group(odds number) and control group(even number).The treatment success rate,treatment outcome,patients’ compliance and side-effect were analyzed in the two groups. Result There was no significant difference between the two group on sex,age,weight,treatment success rate,management method and patients’ compliance(P>0.05).The sputum conversion rate at the end of 2 nd month and 3 rd month were 87.0% and 93.5% in study group,and were 89.4% and 93.5% in the control group.The cure rate was 93.5% in the study group and 87.0% in the control group.The difference on the treatment outcome between the two groups was not statistically significant(P>0.05).Except for tinnitus caused by streptomycin(Fisher’s exact P=0.024),other side-effect caused by anti-TB drug were not significant different between the two groups(P>0.05). Conclusion In the developed area,applying fixed-dose combination in regional TB programe is feasible.

Key words: Pulmonary tuberculosis/prevention and control, Chemotherapy, Fixed-dose combination